OctoPlus N.V. operates as a drug delivery and development company worldwide. It offers drug formulation and manufacturing services to pharmaceutical and biotechnology industries; and a platform of proprietary biodegradable polymers for the injectable pharmaceutical products primarily in proteins and peptides. The company’s products include Locteron, which has completed Phase IIb clinical trials for the treatment of chronic hepatitis C; and OP-145 that is in Phase II clinical trials for the treatment of chronic middle ear infection, as well as for the treatment of mucosal infections caused by gram-positive and gram-negative bacteria. It also provides drug delivery technologies, such as OctoDEX, a dextran-based microsphere delivery technology for proteins and particulate systems; PolyActive, a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules; SynBiosys, a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules; and single-shot hepatitis B vaccines and a single-shot Japanese encephalitis vaccines. In addition, the company offers formulation and manufacturing services in the areas of protein and peptide formulations, freeze drying/spray drying, liposomes, microspheres, solubilisation, emulsions, pulmonary formulations, and poorly water soluble compounds. Further, it provides clinical manufacturing services in the areas of formulations, such as liposomes and microspheres for a range of biologicals, including proteins, vaccines, antibodies, siRNA, and DNA, as well as for low-solubles comprising peptides and small molecules. Additionally, the company offers fill and finish manufacturing services. OctoPlus N.V. was founded in 1995 and is based in Leiden, the Netherlands. As of February 28, 2013, OctoPlus N.V. operates as a subsidiary of Dr. Reddy’s Laboratories SA.